Evidence map›Paper›PMID 34502113›Full record

ArticleInternational journal of molecular sciences2021

Effect of Angiotensin II on Chondrocyte Degeneration and Protection via Differential Usage of Angiotensin II Receptors.

Takashi Nishida, Sho Akashi, Masaharu Takigawa, Satoshi Kubota

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Takashi NishidaDepartment of Biochemistry and Molecular Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8525, Japan.
Sho AkashiDepartment of Biochemistry and Molecular Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8525, Japan.
Masaharu TakigawaAdvanced Research Center for Oral and Craniofacial Sciences, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8525, Japan.
Satoshi KubotaDepartment of Biochemistry and Molecular Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8525, Japan.
Okayama University · JP

Funding

KAKENHI grants from the programs Grants-in-Aid for Challenging Research (Pioneering) #JP20K20611KAKENHI grants from the programs Grants-in-Aid for Scientific Research (B) #JP19H03817KAKENHI grants from the programs Grants-in-Aid for Scientific Research (B) #JP21H03105KAKENHI grants from the programs Grants-in-Aid for Scientific Research (C) #JP17K11641KAKENHI grants from the programs Grants-in-Aid for Scientific Research (C) JP#20K09889
6 · The paper itself

Abstract

The renin-angiotensin system (RAS) controls not only systemic functions, such as blood pressure, but also local tissue-specific events. Previous studies have shown that angiotensin II receptor type 1 (AT

Indexed as

AggrecansAngiotensin IIAngiotensin II Type 1 Receptor BlockersAnimalsCell DifferentiationCell Line, TumorCell ProliferationCells, CulturedChondrocytesConnective Tissue Growth FactorFemaleHumansMatrix Metalloproteinase 9MiceReceptor, Angiotensin, Type 1Acan protein, mouseAggrecansAngiotensin IIAngiotensin II Type 1 Receptor BlockersCCN2 protein, mouseConnective Tissue Growth FactorMatrix Metalloproteinase 9Mmp9 protein, mouseReceptor, Angiotensin, Type 1angiotensin IIangiotensin II type I receptor (AT1R)cellular communication network factor 2 (CCN2)losartanrenin–angiotensin system (RAS)

Identifiers

PMID34502113
PMCPMC8430521
OpenAlexW3195193495

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.